Chemical information of Cannabidiol (CBD)
| Product Name | Cannabidiol powder |
| Synonyms | (-)-Cannabidiol
(-)-trans-Cannabidiol Epidiolex CBD |
| Purity | 99% Isolate / Extrapure Isolate (CBD≥99.5%） |
| CAS Number | 13956-29-1 |
| Drug Class | Cannabinoid |
| InChI Key | QHMBSVQNZZTUGM-ZWKOTPCHSA-N |
| SMILE | CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O |
| Molecular Formula | C21H30O2 |
| Molecular Weight | 314.5 g/mol |
| Monoisotopic Mass | 314.224580195 |
| Melting Point | 66°C |
| Boiling Point | 160 °C – 180 °C |
| Elimination half-life | 18–32 hours |
| Color | White to light yellow crystalline powder |
| Solubility | Soluble in oil, extremely soluble in ethanol and methanol, insoluble in water |
| Storage temp | Room temperature, keep dry and away from light |
| Application | For scientific research purposes only, or as raw materials for downstream product development, or for sale in legitimate countries and regions abroad. Please note these products should not be directly consumed or used for clinical treatment in China mainland |
| Our Core Advantages | l 100% natural extraction, industrial-scale production, stable supply
l Quality assurance (GMPC, ISO22716, KOSHER, HALAL) l Third-party laboratory tested, stable and high content of CBD, THC free l Method HPLC. Heavy metals, residues and microbial meet the standards of CHP, JP and USP |
What is Cannabidiol (CBD) ? Cannabidiol definition
Cannabidiol is a chemical in the Cannabis sativa plant, also known as marijuana or hemp. Over 80 chemicals, known as cannabinoids, have been identified in the Cannabis sativa plant. While delta-9-tetrahydrocannabinol (THC) is the major active ingredient in marijuana, cannabidiol is also obtained from hemp, which contains only very small amounts of THC. Both hemp and marijuana are a genus of Cannabis sativa, but with varying differences.
- Marijuana grows with higher percentages of THC (psychoactive; causes a feeling of “high”), and lower percentages of CBD (non-intoxicating).
- Hemp grows with higher percentages of Cannabidiol (CBD), and lower percentages of THC.
Although THC is easily the most popular cannabinoid due to its psychoactive effects, Cannabidiol (CBD) has gained traction due to its non-intoxicating[2], medicinal benefits. According to the World Health Association, CBD is non-addictive, has no withdraw symptoms, and has a great safety profile, so it is no wonder many are turning to Cannabidiol (CBD) powder for its numerous therapeutic benefits. Most notably, CBD powder may help relieve anxiety disorders[1], inflammatory conditions, and chronic pain.
Phcoker cannabidiol powder, 100% naturally extract from industrial hemp, THC free.
Cannabidiol is most commonly used for seizure disorder (epilepsy). It is also used for anxiety[1], pain, a muscle disorder called dystonia, Parkinson disease, Crohn disease, and many other conditions, but there is no good scientific evidence to support these uses.
Cannabidiol (CBD) and THC relationship
CBD has a complex relationship with its fellow cannabinoid delta-9-tetrahydrocannabinol (THC), which is the major active ingredient in cannabis, and responsible for its euphoric effects of marijuana or hashish.
Unlike THC, CBD is not directly psychoactive in the sense that it does not impart any euphoria or ‘high’. This is not the same as saying CBD is completely non-psychoactive. In the first place, there is copious evidence that CBD modulates the effects of THC. [8] [10]
Secondly, a minority of people (around 5 per cent) report mood-altering CBD side effects, in the same way that some patients can experience psychoactive effects from Tylenol or Advil. However, it is believed the majority of such reports stem from consuming CBD that contains traces of THC. Hence the importance of sourcing Cannabidiol from high quality sources.
How does Cannabidiol work? CBD Mechanism of Action
CBD and THC interact with our bodies in a variety of ways. One of the main ways is by mimicking and augmenting the effects of the compounds in our bodies called “endogenous cannabinoids” – so named because of their similarity to compounds found in the cannabis plant.
Cannabidiol powder has effects on the brain. The exact cause for these effects is not clear. However, cannabidiol seems to prevent the breakdown of a chemical in the brain that affects pain, mood, and mental function. Preventing the breakdown of this chemical and increasing its levels in the blood seems to reduce psychotic symptoms associated with conditions such as schizophrenia. Cannabidiol(CBD) might also block some of the psychoactive effects of delta-9-tetrahydrocannabinol (THC). Also, cannabidiol seems to reduce pain and anxiety[1].
CBD and the Endocannabinoid System (ECS)
The ECS was discovered in the 1990s and is thought to be one of the most vital and vast receptor systems for sustaining good health and has been recognised as an important modulatory system in the function of the brain, endocrine and the immune tissues.
Recent science has found that the ECS does not only respond to Endogenous cannabinoids produced in the body but also responds to external Phytocannabinoids or CBD as a means of enhancing the bodies ECS function.[7]
Within the ECS there are receptors CB1 and CB2, located throughout the body. These neurons are a sort of lock, with cannabinoids acting as the key. CB1 receptors exist in high numbers in the brain, especially in the Hypothalamus, Hippocampus and Amygdala. CB2 receptors occur most commonly in the spleen, tonsils, thymus and the immune cells. The endocannabinoid system plays an import role in homeostasis.
CBD doesn’t interact directly with cannabinoid receptors (CB1 and CB2)[9], but instead, it stimulates the endocannabinoid system to produce its own cannabinoids. In addition, it slows their breakdown by inhibiting the FAAH enzyme, so the endocannabinoids can stay in your body for longer. CBD is a remarkably complex cannabinoid and its interaction with the endocannabinoid system needs to be deeply researched to reveal its full potential.
Is CBD legal? Cannabidiol toxicity
CBD is a non-intoxicating part of the cannabis plant with enormous healing potential[2]. Cannabidiol (CBD) has gained traction due to its non-intoxicating, medicinal benefits. According to the World Health Association, CBD is non-addictive, has no withdraw symptoms, and has a great safety profile. While the Food and Drug Administration (FDA) does not regulate the purity or safety of the substance, CBD is considered safe.
The passage of the 2018 Farm Bill made it legal to sell hemp and hemp products in the U.S. But that doesn’t mean that all hemp-derived cannabidiol products are legal. Since cannabidiol has been studied as a new drug, it can’t be legally included in foods or dietary supplements. Also, cannabidiol can’t be included in products marketed with therapeutic claims. Cannabidiol can only be included in “cosmetic” products and only if it contains less than 0.3% THC. But there are still products labeled as dietary supplements on the market that contain cannabidiol. The amount of cannabidiol contained in these products is not always reported accurately on the product label.
The health benefits of CBD
Approved to Treat Epilepsy
The non-psychoactive properties of CBD make it ideal for therapeutic use. In 2018, the first FDA-approved drug, cannabidiol (Epidiolex), containing CBD was released on the market to treat two different kinds of epilepsy [3] [4] — Dravet syndrome and Lennox-Gastaut syndrome.
The FDA approved the treatment for patients as young as two years old. Studies showed it was effective in comparison to a placebo in reducing the frequency of seizures.
To treat anxiety[1]
Though we need more research, a 2015 medical journal review article looked at CBD and its effect on multiple anxiety disorders, including generalized anxiety disorder, seasonal affective disorder, panic disorder, and post-traumatic stress disorder.
The results showed that there was “strong preclinical evidence” to support the treatment of anxiety disorders with CBD, though more research is needed on long-term dosing.
Can Relieve Pain
Studies have shown that CBD may help reduce chronic pain by impacting endocannabinoid receptor activity, reducing inflammation[6] and interacting with neurotransmitters. When the CBD influences the TRPV1, it is effectively blocking pain signals from reaching the rest of the body. The inference provides solace from aches, swelling, and discomfort.
May Reduce Acne
Acne is a common skin condition that affects more than 9% of the population.
It is thought to be caused by a number of factors, including genetics, bacteria, underlying inflammation and the overproduction of sebum, an oily secretion made by sebaceous glands in the skin.
Based on recent scientific studies, CBD oil may help treat acne due to its anti-inflammatory properties [6] and ability to reduce sebum production.
One test-tube study found that CBD oil prevented sebaceous gland cells from secreting excessive sebum, exerted anti-inflammatory actions and prevented the activation of “pro-acne” agents like inflammatory cytokines.
Another study had similar findings, concluding that CBD may be an efficient and safe way to treat acne, thanks in part to its remarkable anti-inflammatory qualities.
Cannabidiol (CBD) powder usage & application
Research has accelerated as the social, regulatory and legal framework around cannabis consumption is under reform in many parts of the world, generating considerable new data.
Clinical research on CBD powder has included studies on anxiety, cognition, movement disorders and pain.
CBD powder can be taken into the body in multiple ways, including by inhalation of smoke or vapor, as an aerosol spray into the cheek, and orally. It may be dispensed as CBD oil or as a prescription liquid solution.
All over the US, people are rubbing CBD balm onto aching joints, dropping CBD tinctures under tired tongues, popping CBD gummies, and puffing on CBD oil-filled vaporizers in hopes of chilling out.
References:
[1] Cannabidiol as a Potential Treatment for Anxiety Disorders. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Neurotherapeutics. 2015 Oct;12(4):825-36. doi: 10.1007/s13311-015-0387-1.
[2] Cannabidiol Adverse Effects and Toxicity. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901.
[3] Epilepsyand cannabidiol: a guide to treatment. Arzimanoglou A, Brandl U, Cross JH, Gil-Nagel A, Lagae L, Landmark CJ, Specchio N, Nabbout R, Thiele EA, Gubbay O, The Cannabinoids International Experts Panel; Collaborators. Epileptic Disord. 2020 Feb 1;22(1):1-14. doi: 10.1684/epd.2020.1141.
[4] Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Samanta D. Pediatr Neurol. 2019 Jul;96:24-29. doi: 10.1016/j.pediatrneurol.2019.03.014. Epub 2019 Mar 22.
[5] Cannabidiol: State of the art and new challenges for therapeutic applications. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Pharmacol Ther. 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22.
[6] Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Burstein S. Bioorg Med Chem. 2015 Apr 1;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059. Epub 2015 Feb 7.
[7] The Endocannabinoid System and its Modulation by Cannabidiol (CBD). Corroon J, Felice JF. Altern Ther Health Med. 2019 Jun;25(S2):6-14.
[8] A Critical Review of the Role of the Cannabinoid Compounds delta(9)-Tetrahydrocannabinol (delta(9)-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment. Jones É, Vlachou S. Molecules. 2020 Oct 25;25(21):4930. doi: 10.3390/molecules25214930.
[9] The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Pertwee RG. Br J Pharmacol. 2008 Jan;153(2):199-215. doi: 10.1038/sj.bjp.0707442. Epub 2007 Sep 10.
[10] Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and delta(9)-Tetrahydrocannabinol. Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Neuropsychopharmacology. 2018 Jan;43(1):142-154. doi: 10.1038/npp.2017.209. Epub 2017 Sep 6.
